Effects of Silymarin (Milk thistle fruit extract) on liver fibrosis in Nonalcoholic Fatty Liver Disease

Efficacy of Silymarin (Milk Thistle fruit extract) compared to placebo in improving liver fibrosis in patients with non-alcoholic fatty liver disease, a Pilot Study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2017/016

Enrollment

Unknown

Registered

2017-06-19

Start date

2024-03-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease

Interventions

The study will be carried out at the hepatology Out Patient Department of the Bangabandhu Sheikh Mujib Medical University. Consenting patients meeting inclusion/exclusion criteria will be allocated i

one capsule to be taken orally, once daily for 6 months Arm 2: Silymarin 2 capsules (280mg) to be taken orally, once daily for 6 months Arm 3: Silymarin 3 capsules (420mg) to be taken orally, once dai

Eligibility

Inclusion criteria

Inclusion criteria: Fatty liver in ultrasonography of hepatobilliary system

Exclusion criteria

Exclusion criteria: 1. Co-infection with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) 2. History of significant alcoholism

Design outcomes

Primary

Measure	Time frame
Degree of hepatic fibrosis as determined by 1. AST to Platelet Ratio Index 2. Fibroscan of liver [Six months from commencing the treatment]	—

Secondary

Measure	Time frame
SGOT/SGPT ratio [One year]	—

Countries

Bangladesh

Contacts

Public ContactProf. Md. Ayub Al Mamun

Chairman

ayubmamunal@gmail.com

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026